Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (264)	6/25/1999 10:33:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 805

The Aebischer departure makes more sense now, they all must have seen this coming, and made it clear that after the trial, cti would be focusing on the stem cells and scrapping encapsulation: Still, it was a reasonable bet, and the pain has not been any greater than I can endure. By August, all this will be nearly forgotten and the mood will swing back the other direction. I think I had it right in this post techstocks.com I guess it is about time to do the mid-year reality check. Check out this post Message 8011306 There are parts of that message I'd like to take back, Biogen is probably a great long term investment, and sometimes things are expensive or cheap for a reason, but I'm learning...slowly. Suppose I had on that day scrapped my micros and bought these other stocks-- alxn then 13 now 10 axph then 6 now 4 chir then 23 now 20 3/8 enzn then 15 now 18 incy then 27 now 23 3/8 mlnm then 38 now 33 regn then 8 now 7 sepr then 110 now 74 vrtx then 30 now 23 3/8 ...nearly all were losers over the last four months, and those stocks would have been decidedly higher-quality choices than my stuff--those stocks have all had a good deal of positive comments made about them, many from the biotech enthusiasts here on SI--not trying to say that over the long term those are not better stocks, but over the short term, I am still outperforming other possible choices. Now, as I check my account balance, I see I am right back near where I started the year--about 48k, all is not lost, but I really need to think about whether I want Magainin and Cambridge Neuroscience--as well as NTII and CTII (perhaps in August??) to pull me out of this slump. For sure, Rick had good advice on the encapsulation thing, great call. However, the folks at CTII had said there was a 50/50 chance on the pain trial, that was good enough for me for a stock trading near book--that would more than doubled if the trial had worked out. Okay, enough from me today. At least my wife's account is still up for the year, but there is no doubt that this is a tough sector these days. The next list for a mid-year reality check will be from post 22 on the Nifty thread, want to see how RCMac's calls have done so far, will post over there after I do the numbers...